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Abstract
Background: Normalization of gene expression microarrays carrying thousands of genes is based
on assumptions that do not hold for diagnostic microarrays carrying only few genes. Thus, applying
standard microarray normalization strategies to diagnostic microarrays causes new normalization
problems.
Results: In this paper we point out the differences of normalizing large microarrays and small
diagnostic microarrays. We suggest to include additional normalization genes on the small
diagnostic microarrays and propose two strategies for selecting them from genomewide
microarray studies. The first is a data driven univariate selection of normalization genes. The
second is multivariate and based on finding a balanced diagnostic signature. Finally, we compare
both methods to standard normalization protocols known from large microarrays.
Conclusion: Not including additional genes for normalization on small microarrays leads to a loss
of diagnostic information. Using house keeping genes from the literature for normalization fails to
work for certain datasets. While a data driven selection of additional normalization genes works
well, the best results were obtained using a balanced signature.
Background
Several publications have suggested the use of cDNA-
microarrays for clinical diagnosis [1-4]. While today's
microarrays can cover up to 50,000 genes, only a small
percentage of them is needed for diagnosis. Most diagnos-
tic microarray datasets can achieve optimal classification
with no more than 5–50 discriminative genes [5-7]. This
opens new possibilities for the design of small diagnostic
microarrays used for gene expression based diagnosis.
To design such disease specific, small custom arrays differ-
ential genes are identified from a large set of potential can-
didate genes using genome wide expression profiling.
Then, only these differential genes are put onto a small
custom microarray [8]. Throughout this paper, we refer to
diagnostic microarrays as small, custom microarrays for
diagnostic purpose holding only few genes and large
microarrays as genomewide gene expression microarrays,
holding tens of thousands of genes.
With the concept of diagnostic microarrays new problems
arise. A first important step in microarray analysis is nor-
malization. The overall intensity of microarrays can vary
in a large dataset. This can reflect global differential gene
expression, but it is more likely due to experimental arti-
facts. Consequently, array-to-array normalization is cru-
cial for microarray analysis [9-11]. Various methods for
normalization have been suggested. One approach is to
determine a set of invariant genes for normalization
[12,13]. Another approach recommends to replicate genes
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malization [8,14,15].
Standard normalization protocols rely on the assumption
that the majority of genes on the microarray are not differ-
entially expressed between samples [9]. For large microar-
rays this is likely to be true, but on a diagnostic microarray
the genes are selected to be differentially expressed
between disease entities. Consequently, for these diagnos-
tic microarrays a fundamental assumption of microarray
normalization does not hold. This has negative effects on
the quality of gene expression measurements. Assume that
a diagnostic signature consists of 10 genes, all of them
higher expressed in disease type A than in type B. Since
there are also scale differences due to experimental arti-
facts, the microarrays need to be normalized. Normalizing
them to constant average expression also eliminates the
biological differences between A and B. The dilemma is
that global differences can be either artifacts or the mani-
festation of molecular difference between the disease
types. Diagnostic microarrays need to be designed in a
way that allows for the discrimination of these two differ-
ent effects.
One way to address this problem is to include additional
genes on the microarray that are exclusively used for nor-
malization. Typically, one uses housekeeping genes,
which are thought to be expressed at a constant level.
However, it has been found that housekeeping genes are
occasionally regulated, too [16-18].
Therefore, we suggest a data driven approach to select nor-
malization genes from the pool of all genes on the micro-
array. Not only the diagnostic signature should be derived
from the analysis of a large microarray study but we sug-
gest that this data is also used for finding normalization
genes. These are then used for normalizing the diagnostic
microarrays. Note that there is a conceptual difference
between choosing an invariant set of genes from the data
you want to normalize [12,13], and selecting genes from
one dataset (a genome wide expression study) for the pur-
pose of normalizing a second dataset (a diagnostic array).
In the first scenario the variance of genes does not need to
generalize to new data. In the second scenario it does.
Here we address the problem of selecting normalization
genes from a genome wide expression study for the pur-
pose of designing diagnostic arrays. The goal is that the
diagnostic array can then be normalized without prob-
lems. We compare two simple strategies in the context of
simulation experiments as well as in real world applica-
tions. The first strategy aims to find control genes that are
not influenced by the disease type and can therefore be
used for normalization. The second strategy aims to find
genes that complement the discriminatory genes on the
diagnostic microarray in a way such that a normalization
function on all genes together is not any more influenced
by the diseases type. We call this novel concept balanced
signatures.
The paper is organized as follows: First we demonstrate
the problems occurring when standard normalization
protocols are used for diagnostic microarrays. In the
"Methods" section we discuss alternative strategies for
normalization gene selection and the concept of balanced
signatures. In the "Results and Discussion" section we
compare our methods in the setting of a controlled simu-
lation experiment. In the "Results on lung cancer and
leukemia studies" section we show normalization per-
formance on a dataset from a clinical study on leukemia
and on a dataset from a clinical study on lung cancer. We
close with a summary and a discussion of our findings.
Results and discussion
Simulated data
The two normalization methods for diagnostic microar-
rays described in the "Methods" section need to be evalu-
ated with respect to their power in compensating the
global signal normalization effect and producing diagnos-
tic arrays that distinguish well between two disease enti-
ties. Before we evaluate our methods on real data in the
next section we make use of the more transparent setting
of a simulation study, in which the population differ-
ences, the biological variability among individuals and
the experimental variability are modeled independently
of each other.
Simulated data was generated according to a multivariate
normal distribution, including strong correlation of
genes, a large spectrum of expression intensities and non
constant expression differences between the two groups A
and B.
In total we simulated expression values for 3000 genes on
50 microarrays representing two groups A and B of 25
microarrays each. We first generated the covariance matrix
Σ by randomly drawing from an inverse Wishart distribu-
tion with 3150 degrees of freedom and a 3000 × 3000
identity matrix as a scale matrix. Then, we generated a vec-
tor of 3000 population means for each gene i = {1,...,
3000} in each group A and B, ,  by randomly
drawing from a N (0,1) normal distribution for each gene
and group. The actual expression data was generated by
drawing from a multivariate normal distribution with
covariance matrix Σ and means μA for the first 25 microar-
rays and μB for the next 25 microarrays. Finally, this data
was perturbed by multiplying with a random scaling fac-
μi
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N(0,0.3) log-normal distribution. The generation of this
data was done twice. Once for a training set and once for
a test set.
In this simulation with three successive randomization
steps the first step of generating μA, μB and Σ corresponds
to the population properties of the genes. The second step
of drawing from a multivariate N(μA,B, Σ) distribution
accounts for biological variability among individuals,
while the third step of perturbing the data accounts for
global experimental artifacts. The observed differences Δi
display the typical continuous spectrum known from real
expression data (figure 2).
As we have stressed before, the expression patterns of the
normalization genes need to generalize from the training
set where they were found to new data in the same way as
the signature patterns do. From the theoretical considera-
tions of the "Methods" section it becomes clear that small
variance genes have the potential to compensate for the
global signal normalization effect. But the genes need to
have small variances not only on the training data but also
and more importantly on the data that is generated using
the diagnostic array. In general, this variance will be
higher than it is on the training data. The same problem
occurs for genes with small average expression differences
and balanced signatures. To this end, we simulated a
training and a test set with 50 samples. Both sets have the
same underlying gene means and covariance structure. To
avoid overfitting, only the training data was used to select
the normalization genes and only the test set was used to
evaluate the normalization strategies. The diagnostic sig-
nature consists of ps = 10 genes with the largest difference
of population means. It is unbalanced. For the purpose of
normalization pn = 10 additional genes were picked
according to the suggested methods.
Using the standard normalization protocol destroys the
signal completely, while using random normalization
genes already recovers the signal partially (left plot in fig-
ure 3). However, both versions, data based selection of
normalization genes and balanced signatures, recover
population differences more accurately and perform sim-
ilarly to each other (right plot in figure 3).
We repeated the data simulation 30 times and recorded
for each simulation the distance between the real underly-
ing expression differences of the signature genes and the
expression differences obtained by the various normaliza-
tion methods. This sum of squared error plot shows that
all methods achieve significantly better normalization
results compared to the standard method (p < 10-7 using a
paired Wilcoxon test). The balanced signatures also per-
form better than the other proposed methods (figure 4).
In the case of "small effect normalization", "small CV",
and "random" this difference is significant (p < 0.012),
while in the case of "variance normalization" significance
on the 0.05 level was not achieved (p = 0.17).
Two exemplary clinical studies
We now proceed from a simulation study to applications
on real datasets. Of course, in real datasets we do not
know how many genes are deregulated and how many are
necessary for achieving optimal classification accuracy.
Therefore, we ran the MCRestimate package [20], that uses
a nested cross validation loop to avoid biased estimators
of classification performance. Our own results analyzing
various datasets with MCRestimate showed that most data-
sets can be classified optimally with a handful of genes
and only very few need more than 50 (data not shown).
This is in concordance with findings from other authors
[5-7]. When applying it to the leukemia study [2],
described in the "Methods" section, we found that in this
case ps = 5 genes reached the optimal classification accu-
racy of 99%. Thus, we selected ps = 5 signature genes with
the highest absolute equal variance t-score. In addition, pn
= 5 normalization genes were determined according to the
criteria from the "Methods" section. For simplicity, the
number pn of additional genes for normalization was set
to ps. In preliminary studies this provided good results but
further research on determining the optimal ps and pn
simultaneously is needed.
The second dataset we analyzed was a study on 86 primary
lung adenocarcinoma and 10 normal lung tissues [21].
Here, we aimed for a classification of normal versus carci-
noma. MCRestimate achieved 100% accuracy using 3
genes. Thus, we selected ps = pn = 3 for this dataset.
We randomly split the whole datasets equally into a train-
ing and test set. For the training set we applied the gold
standard normalization using all genes of the large micro-
array. Then, we proceeded in the same way as described in
the "Methods" section. Both, signature and normalization
genes were derived using only the training data. For each
sample in the test set a diagnostic microarray was con-
structed using only the raw data of the signature and the
normalization genes. This diagnostic microarray was nor-
malized using the procedure described in the "Methods"
section, resulting in seven different test datasets: standard
protocol, Affymetrix housekeeping genes, random nor-
malization genes, low variances, small coefficient of vari-
ation, small differences and balanced signatures. On the
such normalized test set we evaluated the normalization
methods with respect to the diagnostic performance of a
support vector machine using cross validation. For this,
we used the SVM from the package e1071 in R [22] with a
linear kernel and default parameters. The dataset was ran-
domly split in equally sized training and test sets. This wasPage 3 of 10
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for every data partitioning.
The standard protocol reduces the classification accuracy
substantially, while both normalization gene selection
and balanced signatures yield satisfying results. Affymetrix
housekeeping genes for normalization work well on the
leukemia dataset, but fail on the lung dataset. Balanced
signatures provide the best results in both datasets.
For the leukemia dataset classification accuracy was signif-
icantly better for all our methods as compared to the
standard protocol (p < 10-15). "Balanced normalization"
outperformed all other normalizations (p < 10-8), too.
Standard normalization was also clearly inferior in the
lung dataset (p < 10-14). When further testing "balanced
normalization" against other normalizations p-values
were below 0.001 for all but "small effect normalization"
and "random normalization", where significance was not
reached (p = 0.13 and p = 0.15 respectively).
Conclusion
In this paper we showed that using a standard normaliza-
tion protocol from large microarrays has fatal effects. They
are most pronounced when the diagnostic signature is
unbalanced, containing more up- than down-regulated
genes or vice versa. However, in most microarray datasets
there are more significantly up- than down-regulated
genes or vice versa, emphasizing the need for new normal-
ization strategies. Here, we introduced two strategies to
overcome this problem: normalization gene selection and
balanced signatures. Both gave better results for diagnostic
microarrays than the standard normalization protocol.
Using Affymetrix housekeeping genes performs well in the
analyzed leukemia dataset but does not work for the lung
dataset, indicating that these genes are actively regulated
in these tissues.
As standard normalization protocol we have chosen the
RMA procedure. Of course it is not the only protocol in
use. However, the global signal normalization effect is
generic and not restricted to this protocol. Any normaliza-
tion which assumes unchanged expression for the major-
ity of genes on the microarray is expected to suffer from
the same problem. An advantage of both our methods is
that the normalization genes can be selected with no addi-
tional experimental cost and little computational effort.
In recent publications it was shown that the list of differ-
entially expressed genes are unstable and the overlap of
gene lists from different analysis is small [23-25]. How-
ever, for diagnosis one is not aiming at finding a unique
set of signature genes, but a unique diagnosis of future
patients. There are many datasets containing man differ-
ent sets of genes, which all lead to the same diagnosis. For
the purpose of designing diagnostic arrays it is sufficient
to find one such set.
Hua et al. stressed that optimal feature size depends
strongly on the classifier and feature-label distribution
and that a choice of optimal feature size can greatly
improve accuracy of the classification [26]. Hence, for
assessing how many genes should be used for a diagnostic
microarray we used a nested cross validation for SVMs
[20]. By this, we determined the number of genes making
up the diagnostic signature (ps) and set it to the number of
genes needed for achieving the optimal classification
accuracy.
In conclusion, balanced signatures perform well with
respect to recovering the real underlying signal as well as
for classification. This was verified on a simulated test
dataset as well as on two real microarray datasets. Their
main advantage is that no space on the diagnostic micro-
array is wasted and all genes can be integrated in the diag-
nostic signature.
Methods
Standard microarray normalization protocols can not be
directly applied to diagnostic microarrays because ignor-
ing the special character of normalization on diagnostic
microarrays leads to a loss of the biological signal. To
illustrate this normalization effect on real data, we used a
publicly available dataset on acute lymphocytic leukemia
(ALL) in children [2]. It consists of 327 samples that fall
into different clinical classes characterized by immu-
nophenotype, chromosomal translocations and aberra-
tions. The study was carried out using Affymetrix
HGU95Av2 chips with 12625 probesets covering more
than 9000 known human genes. For these large Affyme-
trix chips we applied a standard normalization protocol
where we preprocessed the data using background correc-
tion followed by probeset summarization and finally nor-
malization on the summary values. Background
correction was done using perfect match (PM) probes
only, ignoring mismatch (MM) probes. Probeset sum-
mary was done using an additive model fitted by a
median polish procedure. Finally, the data was quantile
normalized. We used the RMA package [19] with default
parameters to perform all three steps. Note that the
probeset summarization step takes logarithms of the data
and hence transforms expression levels to an additive
scale. Here, fold changes of molecule abundance corre-
spond to differences in the normalized data.
We now mimic a potential diagnostic microarray for dis-
criminating between patients displaying a TEL-AML trans-
location (group A) and those displaying either a BCR-ABL
or a E2A-PBX1 translocation (group B). To this end, we
discard all data except for the set of genes that is selectedPage 4 of 10
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and additional normalization genes. Of course, this diag-
nostic microarray was not physically built but constructed
in the computer. Nevertheless, it still consists of real data.
More precisely, we chose the 10 most upregulated genes in
group A. To mimic a diagnostic array we went back to the
non-normalized raw data of only these 10 genes and dis-
carded all other expression data. Using only the remaining
raw data of these 10 genes we repeated the same normal-
ization steps that were used for the large Affymetrix micro-
array. Since normalization was not done on an array-by-
array, nor on a gene-by-gene basis, but borrowed informa-
tion across both genes and microarrays the results of the
two normalizations were different although the underly-
ing raw data was identical.
When switching from the large microarray to the diagnos-
tic microarray the expression differences between the two
cytogenetically different groups of patients vanished
almost completely. Normalization of the diagnostic
microarray had destroyed the original signal needed for
diagnosis (Figure 1). We refer to this effect as the global sig-
nal normalization effect. Not only did the expression differ-
ences vanish, but the average correlation between the
genes also changed from 0.73 to -0.1.
We showed that standard normalization applied to diag-
nostic microarrays can substantially skew results and is a
problem for diagnosis. In the following section we pro-
pose two different strategies to circumvent these prob-
lems. The first strategy aims at finding genes that can be
used solely for normalization. Several methods for find-
ing these genes are suggested and compared. The second
strategy aims at finding genes that can be used for normal-
ization and additionally also for classification.
Diagnostic microarray normalization with selected genes
We have argued that a microarray carrying only differen-
tially expressed genes can hardly be used to distinguish
biological effects from experimental artifacts. To over-
come this problem we suggest to include additional nor-
malization genes on a diagnostic microarray that are then
used to adjust for experimental artifacts but leave the bio-
logical signal intact. Like the signature genes, the normal-
ization genes can be selected based on the data from a
genomewide expression study. While signature genes
should correlate with the disease labels of patients, the
normalization genes should not.
For the signature genes it is most important that the corre-
lation of expression levels to the disease labels does not
only hold for the training data on which the genes were
found but generalizes to new samples. In the same way
the desired properties of normalization genes also need to
generalize to new data. Hence, criteria for normalization
need to be chosen such that they enable both, a good nor-
malization of diagnostic microarrays and at the same time
generalize well to new samples. Note that these two
requirements do not implicate each other.
Let ps be the number of genes that form the diagnostic sig-
nature. In experimental settings ps was in the range of 5–
50 genes [5-7]. Let pn be the number of additional genes
used on the microarray for array-to-array normalization.
The total number of genes on the diagnostic microarray is
thus pd = ps + pn. Both the signature genes and the normal-
ization genes are selected based on genomewide microar-
ray data measured with large microarrays holding pl » pd
genes. In this context xij denotes the expression of gene i in
patient j. As we aim at diagnostic differentiation into
groups we can assume without loss of generality that the
samples fall into two different disease entities represented
by class labels A and B. If there should be more classes, it
is always possible to construct a binary classification tree
where the first group is compared to all others. Then the
second group is compared to the rest excluding the first
group and so on.
The open question is how to select normalization genes.
We propose two novel methods. The first method selects
genes solely used for normalization according to criteria
listed below. The second method aims at balancing the
signature and is described in the section "Balanced signa-
tures".
Selection of normalization genes
For the first method we suggest three alternative criteria:
1. Low variance genes
Calculate the empirical variance  of all pl genes and
choose the pn genes with the smallest variance in the data.
Use only these genes for array-to-array normalization. In
our preprocessing protocol the background correction
and probeset summarization remain unchanged but only
these pn genes are used for the final normalization step.
In this approach, we aim for the genes with the most con-
stant expression in both disease populations. Population
variances are not known and we select the genes due to
their variances on the expression data of the genomewide
study. This idea is similar to the use of housekeeping
genes, whose expression is assumed to hardly vary
between patients. Observed differences in measurements
are hence most likely due to experimental artifacts. How-
ever, we do not select housekeeping genes based on a pri-
ori knowledge, but from the data at hand.
σ i
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Calculate the empirical variance  and the empirical
mean μi of all pl genes and choose the pn genes with the
smallest coefficient of variation  in the data. Use only
these pn genes for array-to-array normalization.
In this approach, we aim for the genes with low variance
that additionally have high intensity. The idea is to
exclude low variance genes within the background noise.
3. Small differences of average expression
Calculate the differences Δi = ∑j ∈ JA xij/|JA|-∑j ∈ JB xij/|JB|
between the two groups for all pl genes and choose the pn
genes with the smallest absolute Δi. Use only these genes
for array-to-array normalization.
In this approach we allow the genes to vary between
patients but this variability should not correlate with the
disease type. Note that the genes are typically not constant
and therefore not housekeeping genes. Still they allow for
normalization if the property of small expression differ-
ences generalizes well to the diagnostic microarray.
σ i
2
σ
μ
i
i
Normalization effect on diagnostic microarraysFigure 1
Normalization effect on diagnostic microarrays. The 
global signal normalization effect resulting from standard nor-
malization protocols applied to diagnostic microarrays: 
Shown are changes of expression difference, when switching 
from a large microarray to a diagnostic microarray. The top 
genes are those genes with the maximal expression differ-
ence between TEL-AML versus BCR-ABL and E2A-PBX1. 
Note, that expression differences on log scale reflect fold 
changes.
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ization. Here of course we have no problem with general-
ization. One might expect, that the above methods are
more effective, but this needs to be proved empirically.
For the evaluation of the real datasets we included the
normalization results obtained when using standard
housekeeping genes. For this, we used the following 3'
variants of the housekeeping probe-sets supplied on
Affymetrix GeneChips: beta-actin, GAPDH, ISGF3, 18S
rRNA, transferrin receptor and 28S rRNA.
Balanced signatures
This approach does not use different genes for normaliza-
tion and diagnosis, but tries to find a set of genes, which
serves both tasks at the same time. Starting from a non
balanced set of signature genes, choose pn genes from all pl
genes such that the variation of the average gene expres-
sion per microarray is minimized
where x.j denotes the average expression of genes on the
diagnostic array j, J is the set of all samples, Id is the set of
all genes on the diagnostic microarray and x.. the average
gene expression over all diagnostic microarrays. This is
done using a greedy forward selection, which is summa-
rized in pseudo code. In contrast to the methods above,
the normalization is now done using both signature and
normalization genes. The strategy here is not to find genes
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two disease groups, but genes that compensate this effect.
For example, if the signature genes are all up-regulated in
group A, the goal is to compensate for this effect by choos-
ing genes which are down regulated. This method does
not distinguish between the discriminating genes and the
genes for normalization any more. The normalization
genes are now themselves differentially expressed and can
hence be included into the signature.
In the absence of experimental artifacts the summed up
expression levels for each sample should be constant. In
this way, these genes allow us to distinguish between dif-
ferential expression and experimental artifacts. Similar to
Classification accuracy using different normalization methodsFigure 5
Classification accuracy using different normalization methods. Cross validation results of predictive performance of 
the same diagnostic signature used with different normalization strategies for diagnostic microarrays. The left plot shows clas-
sification accuracies for distinguishing TEL-AML1 from other groups in leukemia (ps = pn = 5). The right plot shows classification 
accuracies for distinguishing normal from adenocarcinomas in lung (ps = pn = 3). The boxplots are sorted by increasing median 
accuracy. When they have the same median the mean was used for sorting.
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lem. We balance the signature on the training set. Its nor-
malization performance for the diagnostic microarray
however depends on how well the balance between up-
and down-regulated genes generalizes to new data.
Normalization of small diagnostic microarrays
Normalization of small diagnostic microarrays was done
by subtracting the sample wise mean of the normalization
genes from all genes. Let xij be the expression of gene i in
patient j. Let In be the set of normalization genes, and pn =
|In| the number of normalization genes. For all normali-
zation genes the sample wise mean Vj was calculated:
. Normalization was then done by sub-
tracting Vj from all genes resulting in normalized data yij:
yij = xij - vj. For the balanced signature In included all genes
and therefore Vj = x.j
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Greedy forward selection
Let: J = JA ∪ JB, be all samples in group A and B, |J| is the
number of all samples
Il, be the set of all genes on the large microarray
Is, be the set of given genes of the diagnostic signature
In = {}, be the initially empty set of normalization genes
for k = 1... pn (for each normalization gene)
Id = Is ∪ In
for g ∈ Il\Id (for each gene on the large microarray not yet
used on the diagnostic microarray) calculate
In = In ∪ argming vg
Pseudo code for greedy forward selection of balancing
genes
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